Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science and Research Institute for Veterinary Science, Seoul National University, Seoul 08826, Republic of Korea.
Haemaru Companion Animal Medical Foundation, Seongnam, Republic of Korea.
J Vet Intern Med. 2024 Jul-Aug;38(4):2158-2164. doi: 10.1111/jvim.17131. Epub 2024 Jun 22.
Romiplostim, a thrombopoietin analog, is commonly used to treat immune-mediated thrombocytopenia (ITP) in humans, but its use in dogs remains limited.
Evaluate the effects and adverse events of romiplostim administration in dogs with thrombocytopenia caused by various underlying diseases.
Forty-two client-owned dogs with naturally occurring thrombocytopenia at 2 referral animal hospitals.
Retrospective, multi-institutional analysis to evaluate the outcomes of romiplostim treatment in dogs.
Among the dogs treated with romiplostim, 27 experienced an increase in platelet count and 26 maintained a platelet count within the reference range. Platelet count improvement was observed in various conditions: primary ITP (90%, n = 18/20), pancytopenia of unknown etiology (42.9%, n = 3/7), chemotherapy-induced thrombocytopenia (50%, n = 3/6), babesiosis (100%, n = 1/1), radiotherapy-induced thrombocytopenia (0%, n = 0/1), and disseminated intravascular coagulopathy (33.3%, n = 2/6). The median time for platelet recovery (>50 000/μL) after romiplostim administration was 4 days, and the median time for platelet count normalization was 7 days. Median hospitalization time for the improvement group (I) was 5 days. The survival-to-discharge rates were 85%, 40%, and 28.6% for dogs with primary ITP, secondary thrombocytopenia, and thrombocytopenia of unknown etiology, respectively.
Romiplostim is a well-tolerated and promising treatment for primary ITP in dogs, suggesting its potential as a valuable therapeutic option for dogs with thrombocytopenia caused by various underlying conditions. These findings emphasize the need for further research to optimize romiplostim dosing and understand its role in treating secondary thrombocytopenia and pancytopenia of unknown etiology.
罗米司亭是一种血小板生成素类似物，常用于治疗人类免疫介导性血小板减少症（ITP），但其在犬中的应用仍有限。
评估罗米司亭在因各种基础疾病导致血小板减少的犬中的疗效和不良反应。
在 2 家转诊动物医院，42 只患有自发性血小板减少症的患犬。
回顾性多机构分析评估罗米司亭治疗犬血小板减少症的结果。
在接受罗米司亭治疗的犬中，27 只犬的血小板计数增加，26 只犬的血小板计数维持在参考范围内。在各种情况下均观察到血小板计数改善：原发性 ITP（90%，20/22）、原因不明的全血细胞减少症（42.9%，3/7）、化疗诱导的血小板减少症（50%，3/6）、巴贝斯虫病（100%，1/1）、放疗诱导的血小板减少症（0%，0/1）和弥散性血管内凝血（33.3%，2/6）。罗米司亭给药后血小板恢复（>50000/μL）的中位时间为 4 天，血小板计数正常化的中位时间为 7 天。改善组（I）的中位住院时间为 5 天。原发性 ITP、继发性血小板减少症和原因不明的血小板减少症犬的存活率至出院率分别为 85%、40%和 28.6%。
罗米司亭是治疗犬原发性 ITP 的一种耐受性良好且有前途的治疗方法，表明其可能成为治疗各种基础疾病导致的犬血小板减少症的有价值的治疗选择。这些发现强调需要进一步研究来优化罗米司亭剂量并了解其在治疗继发性血小板减少症和原因不明的全血细胞减少症中的作用。
